<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163089">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01858896</url>
  </required_header>
  <id_info>
    <org_study_id>HP00055308</org_study_id>
    <nct_id>NCT01858896</nct_id>
  </id_info>
  <brief_title>GLP-1 and Hypoglycemia</brief_title>
  <official_title>Hypoglycemia Associated Autonomic Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low blood sugar can negatively affect how blood vessels function, and this can lead to an
      increase in the risk for heart attacks, strokes and other problems related to the stiffening
      and blockage of blood vessels.  The purpose of this study is to learn if and how
      glucagon-like peptide-1 (GLP-1; a naturally occurring hormone in the gut) changes the
      effects that low blood sugar levels have on blood vessels.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Plasminogen Activation inhibitor-1 (PAi-1)</measure>
    <time_frame>change from baseline to end of clamp period</time_frame>
    <safety_issue>No</safety_issue>
    <description>measurements of change in PAi-1 at baseline and during the end of the glucose clamp period (2 hours)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Flow mediated dilation (FMD)</measure>
    <time_frame>change from baseline and end of clamp</time_frame>
    <safety_issue>No</safety_issue>
    <description>flow mediated dilation of the brachial artery will be measured for change from baseline and end of glucose clamp (~4 hours)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Glucagon-Like Peptide -1 (GLP-1) infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infusion of GLP-1 during experimental period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline infusion during experimental period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon-Like Peptide- 1 (GLP-1) infusion</intervention_name>
    <description>GLP-1 infusion during experimental period</description>
    <arm_group_label>Glucagon-Like Peptide -1 (GLP-1) infusion</arm_group_label>
    <other_name>GLP-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Comparator: Saline Infusion</intervention_name>
    <description>Saline infusion (placebo) during experimental period</description>
    <arm_group_label>Saline Infusion</arm_group_label>
    <other_name>Saline infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  14 (7 males, 7 females) healthy controls age 30-60 yr.

          -  14 (7 males, 7 females) people with type 2 DM age 30-60 yr.

          -  For type 2 DM: HbA1c  6-10.0%

          -  No significant diabetic tissue complications (i.e. history of retinopathy,
             neuropathy, stasis ulcers, etc.)

          -  Body mass index  &gt;25kg â€¢ m-2

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen N Davis, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, Baltimore County</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Donna Tate</last_name>
    <phone>410-706-5643</phone>
    <email>diabetesstudies@medicine.umaryland.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cheryl Young, CRNP</last_name>
    <phone>410-706-5641</phone>
    <email>diabetesstudies@medicine.umaryland.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Maryland, Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Tate</last_name>
      <phone>410-706-5643</phone>
    </contact>
    <contact_backup>
      <last_name>Nino Joy, MD</last_name>
      <phone>410-706-5636</phone>
    </contact_backup>
    <investigator>
      <last_name>Stephen N Davis, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 16, 2013</lastchanged_date>
  <firstreceived_date>May 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Stephen N. Davis</investigator_full_name>
    <investigator_title>Chairman of Medicine</investigator_title>
  </responsible_party>
  <keyword>hypoglycemia</keyword>
  <keyword>GLP-1</keyword>
  <keyword>Type 2 diabetes</keyword>
  <keyword>endothelial function</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
